Your browser doesn't support javascript.
The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19.
Atmowihardjo, Leila; Schippers, Job R; Bartelink, Imke H; Bet, Pierre M; van Rein, Nienke; Purdy, Keith; Cavalla, David; Comberiati, Valérie; McElroy, Andrew; Snape, Sue D; Bogaard, Harm Jan; Heunks, Leo; Juffermans, Nicole; Schultz, Marcus; Tuinman, Pieter R; Bos, Lieuwe D J; Aman, Jurjan.
  • Atmowihardjo L; Dept. of Intensive Care, Amsterdam UMC location AMC, Amsterdam, The Netherlands. l.atmowihardjo@amsterdamumc.nl.
  • Schippers JR; Dept. of Pulmonology, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.
  • Bartelink IH; Hospital Pharmacy, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.
  • Bet PM; Hospital Pharmacy, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.
  • van Rein N; Hospital Pharmacy, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.
  • Purdy K; Exvastat, Cambridge, England.
  • Cavalla D; Exvastat, Cambridge, England.
  • Comberiati V; Simbec-Orion, Merthyr Tydfil, England.
  • McElroy A; Exvastat, Cambridge, England.
  • Snape SD; Exvastat, Cambridge, England.
  • Bogaard HJ; Dept. of Pulmonology, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.
  • Heunks L; Dept. of Intensive Care, Amsterdam UMC, location VUMC, Amsterdam, The Netherlands.
  • Juffermans N; Dept. of Intensive Care, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.
  • Schultz M; Dept. of Intensive Care, Amsterdam UMC location AMC, Amsterdam, The Netherlands.
  • Tuinman PR; Dept. of Intensive Care, Amsterdam UMC, location VUMC, Amsterdam, The Netherlands.
  • Bos LDJ; Dept. of Pulmonology, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.
  • Aman J; Dept. of Pulmonology, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.
Trials ; 23(1): 158, 2022 Feb 16.
Article in English | MEDLINE | ID: covidwho-1690887
ABSTRACT

BACKGROUND:

The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact.

METHODS:

This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 11 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics.

DISCUSSION:

The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay. TRIAL STATUS Protocol version and date V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks. TRIAL REGISTRATION ClinicalTrials.gov NCT04794088 . Registered on 11 March 2021.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / COVID-19 Type of study: Controlled clinical trial / Diagnostic study / Clinical Practice Guide / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: Trials Journal subject: Medicine / Therapeutics Year: 2022 Document Type: Article Affiliation country: S13063-022-06055-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / COVID-19 Type of study: Controlled clinical trial / Diagnostic study / Clinical Practice Guide / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: Trials Journal subject: Medicine / Therapeutics Year: 2022 Document Type: Article Affiliation country: S13063-022-06055-9